Premium
The effect of thyrotoxicosis on isoniazid acetylation.
Author(s) -
Littley MD,
Hutchings A,
Spragg BP,
Routledge PA,
Lazarus JH
Publication year - 1988
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1988.tb03372.x
Subject(s) - isoniazid , euthyroid , acetylation , medicine , antithyroid agent , pharmacology , endocrinology , pediatrics , gastroenterology , chemistry , thyroid , biochemistry , pathology , tuberculosis , graves' disease , gene
Isoniazid acetylation was assessed in 10 thyrotoxic patients before and after standard antithyroid therapy. The group contained five fast and five slow acetylators and all remained within the same phenotypic classification when rendered euthyroid. There was no significant change in the elimination half‐life of isoniazid between thyrotoxicosis and euthyroidism for the group as a whole or for fast and slow acetylators considered separately. Thyrotoxicosis does not appear to be an important determinant of isoniazid acetylation in man.